PDCD1 and neoplasm: The combination therapy of TP-NLC+L and PD-1 blockade effectively inhibited tumor growth, promoted DCs maturation, initiated the CD3+CD8+ TILs expansion and recruitment, and enhanced adaptive antitumor efficiency, thus generating systemic antitumor immune response to suppress the abscopal tumors.